Nectar Lifesciences Limited (BOM:532649)
India · Delayed Price · Currency is INR 14.67
-0.37 (-2.46%)
At close: Aug 28, 2025
Nectar Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 15,918 | 16,700 | 16,841 | 15,237 | 16,688 | 15,433 | Upgrade |
Other Revenue | - | 3.92 | 4.84 | 0.25 | 0.25 | 0.25 | Upgrade |
| 15,918 | 16,704 | 16,846 | 15,237 | 16,689 | 15,433 | Upgrade | |
Revenue Growth (YoY) | -3.49% | -0.84% | 10.56% | -8.70% | 8.13% | -34.78% | Upgrade |
Cost of Revenue | 13,942 | 13,885 | 12,195 | 11,593 | 12,231 | 11,571 | Upgrade |
Gross Profit | 1,976 | 2,819 | 4,650 | 3,644 | 4,457 | 3,862 | Upgrade |
Selling, General & Admin | 967.52 | 985.1 | 865.6 | 796.01 | 763.07 | 751.49 | Upgrade |
Other Operating Expenses | 2,290 | 2,095 | 2,249 | 2,309 | 2,109 | 1,888 | Upgrade |
Operating Expenses | 3,892 | 3,704 | 3,722 | 3,696 | 3,441 | 3,362 | Upgrade |
Operating Income | -1,916 | -884.66 | 928.4 | -51.72 | 1,016 | 499.91 | Upgrade |
Interest Expense | -732.97 | -770.54 | -896.23 | -827.98 | -699.44 | -857.65 | Upgrade |
Interest & Investment Income | - | 14.89 | 123.9 | 17.26 | 18.84 | 26.82 | Upgrade |
Currency Exchange Gain (Loss) | - | 385.27 | 97.5 | 98.78 | 4.68 | -84.92 | Upgrade |
Other Non Operating Income (Expenses) | 16.9 | -360.51 | -72.68 | -65.67 | -93.34 | -177.78 | Upgrade |
EBT Excluding Unusual Items | -2,632 | -1,616 | 180.89 | -829.33 | 246.71 | -593.62 | Upgrade |
Gain (Loss) on Sale of Investments | - | 0.35 | 1.8 | 1.05 | 0.03 | 0.4 | Upgrade |
Gain (Loss) on Sale of Assets | - | -0.14 | - | 404.08 | 94.07 | -1.31 | Upgrade |
Other Unusual Items | - | - | - | - | - | -253.15 | Upgrade |
Pretax Income | -2,632 | -1,615 | 182.69 | -424.2 | 340.81 | -847.68 | Upgrade |
Income Tax Expense | -833.25 | -478.53 | 132.74 | -182.37 | 90.34 | -115.04 | Upgrade |
Net Income | -1,799 | -1,137 | 49.95 | -241.83 | 250.47 | -732.64 | Upgrade |
Net Income to Common | -1,799 | -1,137 | 49.95 | -241.83 | 250.47 | -732.64 | Upgrade |
Shares Outstanding (Basic) | 223 | 224 | 224 | 224 | 224 | 224 | Upgrade |
Shares Outstanding (Diluted) | 223 | 224 | 224 | 224 | 224 | 224 | Upgrade |
EPS (Basic) | -8.06 | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 | Upgrade |
EPS (Diluted) | -8.06 | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 | Upgrade |
Free Cash Flow | - | 1,256 | 1,953 | 1,036 | 700.35 | -98.62 | Upgrade |
Free Cash Flow Per Share | - | 5.60 | 8.71 | 4.62 | 3.12 | -0.44 | Upgrade |
Gross Margin | 12.41% | 16.88% | 27.61% | 23.92% | 26.71% | 25.02% | Upgrade |
Operating Margin | -12.04% | -5.30% | 5.51% | -0.34% | 6.09% | 3.24% | Upgrade |
Profit Margin | -11.30% | -6.81% | 0.30% | -1.59% | 1.50% | -4.75% | Upgrade |
Free Cash Flow Margin | - | 7.52% | 11.59% | 6.80% | 4.20% | -0.64% | Upgrade |
EBITDA | -1,288 | -260.77 | 1,536 | 539.47 | 1,586 | 1,102 | Upgrade |
EBITDA Margin | -8.09% | -1.56% | 9.12% | 3.54% | 9.50% | 7.14% | Upgrade |
D&A For EBITDA | 628.07 | 623.89 | 607.18 | 591.19 | 569.68 | 602.53 | Upgrade |
EBIT | -1,916 | -884.66 | 928.4 | -51.72 | 1,016 | 499.91 | Upgrade |
EBIT Margin | -12.04% | -5.30% | 5.51% | -0.34% | 6.09% | 3.24% | Upgrade |
Effective Tax Rate | - | - | 72.66% | - | 26.51% | - | Upgrade |
Revenue as Reported | 15,961 | 16,750 | 16,987 | 15,668 | 16,802 | 15,471 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.